Hemorrhagic and thromboembolic complications in patients with implanted left ventricular assist devices in early postoperative period
DOI:
https://doi.org/10.25284/2519-2078.3(88).2019.177395Ключові слова:
left ventricular assist device (LVAD), anticoagulant targeted therapy (ACTT), hemorrhagic and thromboembolic complicationsАнотація
The work is devoted to study hemorrhagic and thromboembolic complications in early postoperative period after implantation of left ventricular assist devices (LVAD).
We performed retrospective analysis of 10 patients, males aged 55±13.5 years, with a BMI of 30.8±8.3, with a left ventricular ejection fraction ranging from 9% to 28%, which in the period from 11.03.2016 to 22.11.2017 year, in the Silesian center of the Heart Disease (Poland), in conditions of artificial blood circulation, LVAD was implanted.
In the early postoperative period, patients received daily anticoagulant target therapy (ACCT), consisting of the following drugs: heparin (6-11 U/kg/h), aspirin (75-150 mg), Clopidogrel (75-150 mg), warfarin (1.5-7 mg), Nadroparinum Ca (0.3-0.6 ml/twice on day), Fondaparinux Na (2.5-5 mg/twice on day). Two patients received mono-heparin therapy, one patient received monotherapy with warfarin for 14 days. Other patients during the same period received combined heparin therapy in the first three days with a subsequent transition to warfarin, aspirin, Clopidogrel, Fraxiparin, or thrombin blocker.
The mechanical support of the left ventricle was carried out essentially by two different implantable systems, performing one function of support of the left ventricle: POLVAD – programmed controlled pneumatic membrane mechanical circulation of blood to two patients, and LVAD program-controlled electro-centrifugal circulation for eight patients. The duration of support by POLVAD system was from 102 to 156 days. Length of support – LVAD ranged from 20 to 78 days.
A comparison of the analyzed results led to the conclusion that anticoagulant mono-therapy with heparin or warfarin leads to an increase in the percentage of complications and mortality compared with the alternative combination anticoagulant targeted therapy consisting of the following drugs: heparin (6-11 U/kg/h), aspirin 75-150 mg), Clopidogrel (75-150 mg), warfarin (1.5-7 mg), Nadroparinum Ca (0.3-0.6 ml/ twice on day), Fondaparinux Na (2.5-5 mg/ twice on day), Where survival rates were significantly higher by 60%.
Посилання
Kirklin J.K., Naftel D.C., Pagani F.D., Kormos R.L., Stevenson L.W., Blume E.D., Myers S.L., Miller M.A., Baldwin J.T., Young J.B. Seventh INTERMACS annual report: 15,000 patients and counting. J. Heart. Lung. Transplant. 2015 Dec;34(12):1495-504.
| 
Akhter S.A., Badami A., Murray M., Kohmoto T., Lozonschi L., Osaki S., Lushaj E.B. Hospital Readmissions After Continuous-Flow Left Ventricular Assist Device Implantation: Incidence, Causes, and Cost Analysis. Ann. Thorac. Surg. 2015 Sep;100(3):884-9.
|
Wever-Pinzon O., Drakos S.G., Kfoury A.G., Nativi J.N., Gilbert E.M., Everitt M., Alharethi R., Brunisholz K., Bader F.M., Li D.Y., Selzman C.H., Stehlik J. Morbidity and mortality in heart transplant candidates supported with mechanical circulatory support: is reappraisal of the current United network for organ sharing thoracic organ allocation policy justified? Circulation. 2013 Jan 29;127(4):452-62
|
Amornsawadwattana S., Nassif M., Raymer D., LaRue S., Chen C.H. Video capsule endoscopy in left ventricular assist device recipients with obscure gastrointestinal bleeding. World J. Gastroenterol. 2016 May 14;22(18):4559-66.
|
Kushnir V.M., Sharma S., Ewald G.A., Seccombe J., Novak E., Wang I.W., Joseph S.M., Gyawali C.P.. Evaluation of GI bleeding after implantation of left ventricular assist device. Gastrointest Endosc. 2012 May;75(5):973-9.
|
Crow S., Chen D., Milano C., Thomas W., Joyce L., Piacentino V., Sharma R., Wu J., Arepally G., Bowles D., Rogers J., Villamizar-Ortiz N. Acquired von Willebrand syndrome in continuous-flow ventricular assist device recipients. Ann. Thorac. Surg. 2010;90(4):1263-9.
|
Meyer A.L., Malehsa D., Bara C., Budde U., Slaughter M.S., Haverich A., Strueber M. Acquired von Willebrand syndrome in patients with an axial flow left ventricular assist device. Circ. Heart Fail. 2010;3(6):675-81.
|
Slaughter M.S., Rogers J.G., Milano C.A., Russell S.D., Conte J.V., Feldman D., Sun B., Tatooles A.J., Delgado R.M., Long J.W., Wozniak T.C., Ghumman W., Farrar D.J., Frazier O.H. HeartMate II Investigators. Advanced heart failure treated with continuous-flow left ventricular assist device. N. Engl. J. Med. 2009 Dec 3;361(23):2241-51.
|
Saeed O., Shah A., Kargoli F., Madan S., Levin A.P., Patel S.R., Jermyn R., Guerrero C., Nguyen J., Sims D.B., Shin J., D’Alessandro D., Goldstein D.J., Jorde U.P. Antiplatelet Therapy and Adverse Hematologic Events During Heart Mate II Support. Circ Heart Fail. 2016 Jan;9(1):e002296.
|
Bunte M.C., Blackstone E.H., Thuita L., Fowler J., Joseph L., Ozaki A., Starling R.C., Smedira N.G., Mountis M.M. Major bleeding during HeartMate II support. J. Am. Coll. Cardiol. 2013 Dec 10;62(23):2188-96.
|
Wever-Pinzon O., Selzman C.H., Drakos S.G., Saidi A., Stoddard G.J., Gilbert E.M., Labedi M., Reid B.B., Davis E.S., Kfoury A.G., Li D.Y., Stehlik J., Bader F. Pulsatility and the risk of nonsurgical bleeding in patients supported with the continuous-flow left ventricular assist device HeartMate II. Circ Heart Fail. 2013 May;6(3):517-26.
|
Boyle A.J., Russell S.D., Teuteberg J.J., Slaughter M.S., Moazami N., Pagani F.D., Frazier O.H., Heatley G., Farrar D.J., John R. Low thromboembolism and pump thrombosis with the HeartMate II left ventricular assist device: analysis of outpatient anti-coagulation. J. Heart Lung. Transplant. 2009 Sep;28(9):881-7.
|
Nassif M.E., LaRue S.J., Raymer D.S., Novak E., Vader J.M., Ewald G.A., Gage B.F. Relationship Between Anticoagulation Intensity and Thrombotic or Bleeding Outcomes Among Outpatients With Continuous-Flow Left Ventricular Assist Devices. Circ. Heart Fail. 2016 May;9(5).
|
Harvey L., Holley C., Roy S.S., Eckman P., Cogswell R., Liao K., John R. Stroke After Left Ventricular Assist Device Implantation: Outcomes in the Continuous-Flow Era. Ann. Thorac. Surg. 2015;100(2):535-41.
|
Morgan J.A., Brewer R.J., Nemeh H.W., Gerlach B., Lanfear D.E., Williams C.T., Paone G. Stroke while on long-term left ventricular assist device support: incidence, outcome, and predictors. ASAIO J. 2014 May-Jun;60(3):284-9.
|
Xia Y., Stern D., Friedmann P., Goldstein D.. Preoperative atrial fibrillation may not increase thromboembolic events in left ventricular assist device recipients on midterm follow-up. J. Heart. Lung. Transplant. 2016;35(7):906-12.
|
Najjar S.S., Slaughter M.S., Pagani F.D., Starling R.C., McGee E.C., Eckman P., Tatooles A.J., Moazami N., Kormos R.L., Hathaway D.R., Najarian K.B., Bhat G., Aaronson K.D., Boyce S.W.; HVAD Bridge to Transplant ADVANCE Trial Investigators. An analysis of pump thrombus events in patients in the HeartWare ADVANCE bridge to transplant and continued access protocol trial. J. Heart Lung. Transplant. 2014 Jan;33(1):23-34.
|
Uriel N., Morrison K.A., Garan A.R., Kato T.S., Yuzefpolskaya M., Latif F., Restaino S.W., Mancini D.M., Flannery M., Takayama H., John R., Colombo P.C., Naka Y., Jorde U.P.. Development of a novel echocardiography ramp test for speed optimization and diagnosis of device thrombosis in continuous-flow left ventricular assist devices: the Columbia ramp study. J. Am. Coll. Cardiol. 2012 Oct 30;60(18):1764-75.
|
Maltais S., Kilic A., Nathan S., Keebler M., Emani S., Ransom J., Katz J.N., Sheridan B., Brieke A., Egnaczyk J., Entwistle J.W., Adamson R., Stulak J., Uriel N., O’Connell J.B., Farrar D.J., Sundareswaran K.S., Gregoric I. PREVENtion of HeartMate II Pump Thrombosis Through Clinical Management (PREVENT). J. Heart Lung. Transplant. 2016;35(4):S161-S162.
Starling R.C., Moazami N., Silvestry S.C., Ewald G., Rogers J.G., Milano C.A., Rame J.E., Acker M.A., Blackstone E.H., Ehrlinger J., Thuita L., Mountis M.M., Soltesz E.G., Lytle B.W., Smedira N.G. Unexpected abrupt increase in left ventricular assist device thrombosis. N. Engl. J. Med. 2014;370(1):33-40.
|
Saeed D., Maxhera B., Albert A., Westenfeld R., Hoffmann T., Lichtenberg A. Conservative approaches for HeartWare ventricular assist device pump thrombosis may improve the outcome compared with immediate surgical approaches. Interact. Cardiovasc. Thorac. Surg. 2016;23(1):90-5.
|
Mandeep R. Mehra, M.D., Daniel J. Goldstein, M.D., Nir Uriel, M.D., Joseph C. Cleveland, Jr., M.D.et al.,for the MOMENTUM 3 Investigators “Two-Year Outcomes with Magnetically Levitated Cardiac Pump in Heart Failure.” New England Journal of Medicine. IE.
|
##submission.downloads##
Як цитувати
Номер
Розділ
Ліцензія
Авторське право (c) 2019 Біль, знеболення та інтенсивна терапія
Ця робота ліцензується відповідно до Creative Commons Attribution-NonCommercial 4.0 International License.
Автори, які публікуються у цьому журналі, погоджуються з наступними умовами:
a. Автори залишають за собою право на авторство своєї роботи та передають журналу право першої публікації цієї роботи на умовах ліцензії Creative Commons Attribution-NonCommercial 4.0 International License, котра дозволяє іншим особам вільно розповсюджувати опубліковану роботу з обов'язковим посиланням на авторів оригінальної роботи та першу публікацію роботи у цьому журналі.
b. Автори мають право укладати самостійні додаткові угоди щодо неексклюзивного розповсюдження роботи у тому вигляді, в якому вона була опублікована цим журналом (наприклад, розміщувати роботу в електронному сховищі установи або публікувати у складі монографії), за умови збереження посилання на першу публікацію роботи у цьому журналі.
c. Політика журналу дозволяє і заохочує розміщення авторами в мережі Інтернет (наприклад, у сховищах установ або на особистих веб-сайтах) рукопису роботи, як до подання цього рукопису до редакції, так і під час його редакційного опрацювання, оскільки це сприяє виникненню продуктивної наукової дискусії та позитивно позначається на оперативності та динаміці цитування опублікованої роботи (див. The Effect of Open Access).
